Published in Liver Transpl on April 01, 2010
Cryptogenic chronic hepatitis and its changing guise in adults. Dig Dis Sci (2011) 1.50
Liver transplantation and non-alcoholic fatty liver disease. World J Gastroenterol (2014) 1.17
Autoantibody-negative autoimmune hepatitis. Dig Dis Sci (2011) 1.03
Non-alcoholic fatty liver disease: a practical approach to treatment. Frontline Gastroenterol (2014) 1.01
Epidemiology and Natural History of Non-alcoholic Fatty Liver Disease. J Clin Exp Hepatol (2012) 0.88
Equivalent survival following liver transplantation in patients with non-alcoholic steatohepatitis compared with patients with other liver diseases. HPB (Oxford) (2012) 0.85
Non-alcoholic fatty liver disease and liver transplantation: outcomes and advances. World J Gastroenterol (2013) 0.84
Morbid obesity in liver transplant recipients adversely affects longterm graft and patient survival in a single-institution analysis. HPB (Oxford) (2014) 0.84
Liver Transplantation for Nonalcoholic Steatohepatitis in the US: Temporal Trends and Outcomes. Dig Dis Sci (2017) 0.82
The Global Nonalcoholic Fatty Liver Disease Epidemic: What a Radiologist Needs to Know. J Clin Imaging Sci (2015) 0.82
NAFLD and liver transplantation: Current burden and expected challenges. J Hepatol (2016) 0.81
Nonalcoholic Fatty Liver Disease: Key Considerations Before and After Liver Transplantation. Dig Dis Sci (2016) 0.81
Liver transplantation for nonalcoholic fatty liver disease: new challenges and new opportunities. World J Gastroenterol (2014) 0.80
Recurrence of nonalcoholic fatty liver disease after liver transplantation: it is common, but does it affect outcome? Liver Transpl (2010) 0.78
Risk of de novo post-transplant type 2 diabetes in patients undergoing liver transplant for non-alcoholic steatohepatitis. BMC Gastroenterol (2015) 0.78
Republished: Non-alcoholic fatty liver disease: a practical approach to treatment. Postgrad Med J (2015) 0.76
Limitations and opportunities of non-invasive liver stiffness measurement in children. World J Hepatol (2017) 0.75
Hepatobiliary quiz-7 (2013). J Clin Exp Hepatol (2013) 0.75
Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease. World J Gastroenterol (2016) 0.75
Focal fat masquerading as malignancy in the liver graft of a post-transplant patient. Dig Dis Sci (2011) 0.75
Medical Management of Metabolic Complications of Liver Transplant Recipients. Gastroenterol Hepatol (N Y) (2016) 0.75
Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies. J Clin Transl Hepatol (2017) 0.75
Early Intervention With Live Donor Liver Transplantation Reduces Resource Utilization in NASH: The Toronto Experience. Transplant Direct (2017) 0.75
Bariatric Surgery and Liver Transplantation. Gastroenterol Hepatol (N Y) (2017) 0.75
Cardiovascular assessment in liver transplant for non-alcoholic steatohepatitis patients: What we do, what we should do. World J Hepatol (2017) 0.75
Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology (2009) 5.87
Ascitic fluid lactoferrin for diagnosis of spontaneous bacterial peritonitis. Gastroenterology (2008) 2.23
Acute kidney injury following liver transplantation: definition and outcome. Liver Transpl (2009) 2.05
Prospective examination of effects of smoking abstinence on cortisol and withdrawal symptoms as predictors of early smoking relapse. Drug Alcohol Depend (2004) 1.91
Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. Hepatology (2003) 1.76
Attenuated adrenocorticotropic responses to psychological stress are associated with early smoking relapse. Psychopharmacology (Berl) (2005) 1.70
Patients with NASH and cryptogenic cirrhosis are less likely than those with hepatitis C to receive liver transplants. Clin Gastroenterol Hepatol (2011) 1.57
Twenty years of follow-up of aortohepatic conduits in liver transplantation. Liver Transpl (2008) 1.53
Interobserver agreement in hepatitis C grading and staging and in the Banff grading schema for acute cellular rejection: the "hepatitis C 3" multi-institutional trial experience. Arch Pathol Lab Med (2006) 1.49
Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin. Hepatology (2002) 1.40
High-dose angiotensin-converting enzyme inhibition restores body fluid homeostasis in heart-transplant recipients. J Am Coll Cardiol (2003) 1.39
Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol (2010) 1.35
Economic model of a birth cohort screening program for hepatitis C virus. Hepatology (2012) 1.28
Indications for liver transplantation. Gastroenterology (2008) 1.28
Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation. Liver Transpl (2009) 1.22
Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation. Liver Transpl (2012) 1.18
An outcome comparison between primary liver transplantation and retransplantation based on the pretransplant MELD score. Transpl Int (2006) 1.11
Expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation. Liver Transpl (2007) 1.10
Donor-specific human leukocyte antigen antibodies of the immunoglobulin G3 subclass are associated with chronic rejection and graft loss after liver transplantation. Liver Transpl (2012) 1.10
De novo tumors after liver transplantation: a single-institution experience. Liver Transpl (2002) 1.00
Hepatitis C immune globulin to prevent HCV recurrence after liver transplantation: chasing windmills? Liver Transpl (2006) 0.98
A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transpl (2011) 0.97
Late acute rejection after liver transplantation impacts patient survival. Clin Transplant (2008) 0.96
Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transpl (2004) 0.96
A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy. Antivir Ther (2006) 0.93
Hepatorenal syndrome: a proposal for kidney after liver transplantation (KALT). Liver Transpl (2007) 0.93
Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transpl (2002) 0.90
Societal reintegration after liver transplantation: findings in alcohol-related and non-alcohol-related transplant recipients. Ann Surg (2004) 0.90
The prevalence of hepatitis C virus infection in Texas: implications for future health care. Proc (Bayl Univ Med Cent) (2005) 0.89
Future trends in hepatology: challenges and opportunities. Hepatology (2008) 0.89
Liver transplantation and health-related quality of life: scoring differences between men and women. Liver Transpl (2004) 0.88
Conivaptan increases serum sodium in hyponatremic patients with end-stage liver disease. Liver Transpl (2009) 0.87
Preformed class II donor-specific antibodies are associated with an increased risk of early rejection after liver transplantation. Liver Transpl (2013) 0.87
Radiofrequency thermal ablation of hepatocellular carcinoma before liver transplantation--a clinical and histological examination. Clin Transplant (2006) 0.86
Antibody-mediated rejection as a contributor to previously unexplained early liver allograft loss. Liver Transpl (2014) 0.85
A microplate assay specific for the enzyme aggrecanase. Anal Biochem (2003) 0.85
Impact of donor-specific antibodies on results of liver transplantation. Curr Opin Organ Transplant (2013) 0.85
Indications for combined liver and kidney transplantation: propositions after a 23-yr experience. Clin Transplant (2010) 0.85
Donor-specific alloantibodies are associated with fibrosis progression after liver transplantation in hepatitis C virus-infected patients. Liver Transpl (2014) 0.84
Hepatitis C screening: summary of recommendations from the clinical decision tool. Gastroenterology (2013) 0.83
Effect of telaprevir on the pharmacokinetics of sirolimus in liver transplant recipients. Liver Transpl (2013) 0.83
Tailoring antiviral therapy in hepatitis C. Hepatology (2006) 0.83
Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C. Am J Gastroenterol (2003) 0.82
Improved results of transplantation for hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation. Liver Transpl (2009) 0.82
Lack of antiviral effect of a short course of mycophenolate mofetil in patients with chronic hepatitis C virus infection. Liver Transpl (2003) 0.81
Post-liver transplant survival in hepatitis C patients is improving over time. Liver Transpl (2009) 0.81
Endovascular caudal retraction of the cranial end of a misplaced Viatorr TIPS prior to liver transplantation. Proc (Bayl Univ Med Cent) (2012) 0.81
Hepatitis C virus: a critical appraisal of approaches to therapy. Clin Gastroenterol Hepatol (2008) 0.81
Utilization of hepatitis C antibody-positive livers: genotype dominance is virally determined. Transpl Int (2012) 0.80
Intramuscular hepatitis B immunoglobulin (HBIG) and nucleosides for prevention of recurrent hepatitis B following liver transplantation: comparison with other HBIG regimens. Clin Transplant (2007) 0.80
Long-term follow-up of liver transplantation for Budd-Chiari syndrome with antithrombotic therapy based on the etiology. Transplantation (2011) 0.79
Baylor Regional Transplant Institute: an update on liver, kidney, and pancreas transplantation. Proc (Bayl Univ Med Cent) (2003) 0.78
Acute liver allograft antibody-mediated rejection: an inter-institutional study of significant histopathological features. Liver Transpl (2014) 0.78
Whole-organ pancreas transplantation at Baylor Regional Transplant Institute: a chance to cure diabetes. Proc (Bayl Univ Med Cent) (2010) 0.78
Intraoperative imaging of pancreas transplant allografts using indocyanine green with laser fluorescence. Proc (Bayl Univ Med Cent) (2008) 0.78
Twenty years' follow-up of portal vein conduits in liver transplantation. Liver Transpl (2009) 0.78
The challenge of progressive hepatitis C following liver transplantation. Liver Transpl (2006) 0.77
Hepatitis C virus replication and potential targets for direct-acting agents. Therap Adv Gastroenterol (2010) 0.77
Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis C. Clin Gastroenterol Hepatol (2008) 0.77
The evolving treatment of chronic hepatitis C: where we stand a decade out. Cleve Clin J Med (2004) 0.76
Inferior vena cava stent resolves hepatopulmonary syndrome in an adult with a spontaneous inferior vena cava-portal vein shunt. Liver Transpl (2009) 0.76
Impact of birth cohort screening for hepatitis C. Curr Gastroenterol Rep (2014) 0.76
Renal-sparing immunosuppressive protocol using OKT3 after liver transplantation: a 19-year single-institution experience. Proc (Bayl Univ Med Cent) (2011) 0.76
Management of ascites in patients with end-stage liver disease. Rev Gastroenterol Disord (2004) 0.76
Incidence and severity of respiratory insufficiency detected by transcutaneous carbon dioxide monitoring after cardiac surgery and intensive care unit discharge. Proc (Bayl Univ Med Cent) (2013) 0.75
Use of two expanded-criteria-donor renal allografts in a single patient. Proc (Bayl Univ Med Cent) (2007) 0.75
Use of general anesthetic only vs general anesthetic combined with paravertebral block for perioperative pain management after first rib resection. Proc (Bayl Univ Med Cent) (2002) 0.75
Gary L. Davis, MD: a conversation with the editor. Interview by William Clifford Roberts. Proc (Bayl Univ Med Cent) (2003) 0.75
Effect of tacrolimus on survival in hepatitis C-infected patients after liver transplantation. Proc (Bayl Univ Med Cent) (2011) 0.75
Combined cardiac and liver transplantation for the treatment of familial amyloidosis. Proc (Bayl Univ Med Cent) (2007) 0.75
Non-HLA Antibodies Impact on C4d staining, Stellate Cell Activation and Fibrosis in Liver Allografts. Transplantation (2017) 0.75
Basic statistical concepts in nutrition research. Nutr Clin Pract (2013) 0.75
The Baylor Regional Transplant Institute: review of a twenty-year experience. Clin Transpl (2004) 0.75
Tumor biology and pre-transplant locoregional treatments determine outcomes in patients with T3 hepatocellular carcinoma undergoing liver transplantation. Clin Transplant (2013) 0.75
The significance of heparin-coated veno-venous bypass circuits in liver transplantation. Perfusion (2002) 0.75
Chronic AMR in Liver Transplant: Validation of the 1-Year cAMR score's Ability to Determine Long-Term Outcome. Transplantation (2017) 0.75
Best of the AASLD. Highlights from the 52nd Annual Meeting of the American Association for the Study of Liver Diseases. November 9-13, 2001, Dallas, TX. Rev Gastroenterol Disord (2002) 0.75
Clinical vignettes in geriatric depression. Am Fam Physician (2011) 0.75